GRAIL, Inc. (NASDAQ:GRAL) Stock Has Consensus Price Target of $93.60

Shares of GRAIL, Inc. (NASDAQ:GRAL) have received an average rating of “Hold” from the twelve analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $102.70.

A number of research analysts have weighed in on the stock. Mizuho upped their price objective on shares of GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a research report on Friday, September 25th. UBS Group raised their target price on GRAIL from $105.00 to $175.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Canaccord Genuity Group upped their price target on GRAIL from $80.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 28th. Finally, Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a research report on Sunday, September 13th.

Insider Buying and Selling at GRAIL

In other news, CEO Joshua J. Ofman sold 61,452 shares of the business’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the completion of the sale, the chief executive officer owned 362,271 shares of the company’s stock, valued at $35,408,367.54. The trade was a 14.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 4,100 shares of the company’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $93.34, for a total transaction of $382,694.00. Following the transaction, the chief financial officer owned 248,983 shares of the company’s stock, valued at approximately $23,240,073.22. This trade represents a 1.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 78,452 shares of company stock valued at $7,485,691. 1.83% of the stock is owned by insiders.

Institutional Investors Weigh In On GRAIL

Several institutional investors have recently bought and sold shares of GRAL. Caitong International Asset Management Co. Ltd acquired a new position in shares of GRAIL during the fourth quarter valued at approximately $28,000. Fifth Third Bancorp boosted its stake in shares of GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after acquiring an additional 472 shares during the last quarter. Allworth Financial LP acquired a new stake in shares of GRAIL in the second quarter worth approximately $35,000. Geneos Wealth Management Inc. boosted its stake in shares of GRAIL by 160.0% in the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after acquiring an additional 360 shares during the last quarter. Finally, Osbon Capital Management LLC purchased a new stake in shares of GRAIL during the fourth quarter worth approximately $51,000.

GRAIL Stock Performance

Shares of GRAL stock opened at $143.26 on Friday. The stock has a 50 day moving average of $85.11 and a 200 day moving average of $69.01. The stock has a market cap of $6.40 billion, a P/E ratio of -14.69 and a beta of 2.83. GRAIL has a twelve month low of $41.50 and a twelve month high of $151.46.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping the consensus estimate of ($2.66) by $0.10. The business had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. On average, research analysts predict that GRAIL will post -10.41 earnings per share for the current fiscal year.

GRAIL Company Profile

GRAIL, Inc is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw.